Regeneron’s stock is having its worst day in 14 years after the failure of late-stage trial of its COPD treatment, after analysts had just placed a high probability of a positive result.

Regeneron Pharmaceuticals (REGN) has been in a persistent downtrend for over 280 days. The stock is currently in the 10th Phase of its 18-Phase Adhishthana Cycle, our proprietary cyclical framework.

Regeneron Pharmaceuticals has a price-to-sales (P/S) ratio of 4.6 versus a figure of 3.0 for the S&P 500 Moreover, the company’s price-to-free cash flow (P/FCF) ratio stands at 16.4 in contrast ...

A COPD treatment for former smokers developed by Regeneron Pharmaceuticals and Sanofi failed to meet its primary endpoint in one Phase 3 trial. A second test of the drug, itepekimab, was successful.

Regeneron shareholders will be glad to learn that the drugmaker's $256 million bid does not include Lemonaid Health, the telehealth operation that 23andMe acquired for $400 million in 2021.

Regeneron acquired 23andMe for $256M, gaining 15M DNA profiles to enhance R&D. Find out why REGN stock is a Buy.

Regeneron announced the purchase Monday. In March, 23andMe initiated voluntary Chapter 11 proceedings in the U.S. Bankruptcy Court to be sold. 23andMe offers DNA testing with an ancestry breakdown ...

Regeneron Pharmaceuticals’ $256 million offer was chosen the winner of 23andMe’s bankruptcy auction. Drug research never became a big part of the genetic testing company’s business, but it ...

Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million, two months after the genetic testing company filed for Chapter 11 bankruptcy protection.